Background TPO-mimetic agents are definite second-line management for ITP patients promoting development and maturation of megakaryocyte lineage.Platelet count usually drops back to baseline level with rising risk of bleeding posterior to discontinuation of the agents that long-term administration is commonly required to maintain response.